Publiziert in: Marktpuls, Unternehmen
Frei

Ypsomed expands offering for clinical studies Donnerstag, 08. Januar 2026 - 08:00

LOG_Ypsomed.png

Media release

Ypsomed expands offering for clinical studies

Burgdorf, 08.01.2026, 7 a.m. – Ypsomed (SIX: YPSN) is expanding its clinical excellence offering to support faster and more reliable clinical trials for subcutaneous injectable drugs. With CliniPilot and the Clear-to-Clinic approach, Ypsomed combines ready-to-use devices with digital solutions to accelerate clinical evaluation of new therapies.

Social_FB_LinkedIn-YDS_SP_2.25_PWP_0763g.jpg

"By integrating digital solutions and proven device platforms, we strive to make clinical trials more efficient, reliable, and patient-friendly," says Ulrike Bauer, Chief Business Officer at Ypsomed. "Our goal is to help our partners bring innovative therapies faster to patients." 

Faster trial starts and reliable data    

Clear-to-Clinic enables predictable and rapid trial starts by using pre-validated autoinjector platforms. Standardized, ready-to-use devices shorten development timelines and reduce risks, particularly in early clinical phases. CliniPilot complements the YpsoMate platform by providing automated injection data to support study design and decision making. Improved visibility into patient adherence supports data-driven decisions for later study phases and contributes to high-quality trial outcomes. 

More patient-friendly clinical trials     

CliniPilot supports decentralized and hybrid clinical trials by integrating seamlessly into patients' daily routines. Clear injection guidance and automated data capture help reduce patient burden and anxiety. By replacing manual diaries and reducing the need for unnecessary site visits, CliniPilot benefits both patients and study teams. This supports recruitment efforts and improves overall trial efficiency. 

Validated technology and efficient supply

CliniPilot is based on Ypsomed's FDA-cleared SmartPilot platform and is compatible with YpsoMate 1.0 and YpsoMate 2.25 autoinjectors. It works with common electronic data capture systems and requires no additional regulatory steps. Together with Clear-to-Clinic, packaged clinical supplies can be available within six months. Ypsomed coordinates device supply, digital integration, and documentation to ensure smooth execution and regulatory readiness. 

A trusted partner for clinical development 

With its clinical excellence offering, Ypsomed supports pharmaceutical partners throughout clinical development. By combining innovative devices, digital trial solutions, and expert support, Ypsomed helps reduce complexity, control timelines, and improve trial outcomes. 

Contact

Susanne Koehler, Head of Public Relations, Ypsomed Holding AG
+41 34 424 47 32 susanne.koehler@ypsomed.com

This communication and the media material can be found at Media services - Ypsomed.

Ypsomed Group

Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid medication. As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Backed by a proven track record, Ypsomed offers the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions. Ypsomed is headquartered in Burgdorf, Switzerland, and operates a global network of manufacturing facilities. More than 2 000 employees worldwide are committed every day to making selfcare simpler and easier.

Ypsomed AG, Brunnmattstrasse 6, 3401 Burgdorf
info@ypsomed.com, www.ypsomed.com